OneSource Speci. Q2 FY26 Earnings Call — Analysis (NSE: ONESOURCE)

OneSource reiterates FY28 $500M revenue target and accelerates DDC capacity to 200M+ units by end‑CY26, but cautions that the next two quarters face revenue‑recognition ambiguity as partner regulatory approvals remain outside the company's control.

28 Jun 2026 · Analysis by Alpha Inflection

The take

Q2FY26 Revenue ₹375.8 Cr ( +12% YoY ) . New guidance — FY28 base‑business revenue (ex‑acqui… $400 million . New story: Capacity Build‑out Arms Race .

Financial highlights

What management committed to

• FY28 base‑business revenue target of $400M — $400 million, FY28
• FY28 revenue target of $500M including [the announced acquisitions in Poland and Brookes], subject to shareholder approvals — $500 million, FY28
• [OneSource] will begin consolidating the newly announced [Poland and Brookes] businesses from the next financial year [FY27], subject to regulatory and shareholder approvals — FY27
• DDC installed capacity of over 200 million units will be fully ready by end of calendar year 2026, roughly one year ahead of [previously announced schedule] — over 200 million units, CY26
• Capacity expansion will be added in phases: some capacity by May‑June [2026], some by September‑October [2026], and the remainder by end of [calendar] year [2026] — CY26
• [OneSource] expects to be in the [Indian semaglutide] market on day one, as some partners have already received approval — Q4FY26
• [OneSource] expects partner approvals in emerging markets [Brazil, Saudi Arabia, MENA] to open from the last week of March [2026], with significant invoicing from Q1 [FY27] — Q1FY27
• 8 to 10 customers will launch [semaglutide] across multiple global markets in FY27 — 8 to 10 customers, FY27
• [OneSource's] installed biologics capacity of 4,000 liters [mammalian] will be fully taken and will need instant expansion — 4,000 liters, FY27
• The next [DDC capacity] expansion will take place outside India, with the recently acquired Warsaw facility being a potential site
• [OneSource's] working capital will normalize over the medium term as the planned inventory buildup for DDC launches converts — FY27
• [OneSource's] current [Phase 2] DDC capacity expansion will suffice for the medium‑term outlook; further expansion will be evaluated as needed — FY28

How the narrative shifted

• Regulatory Ambiguity & Revenue‑Recognition Gap: Management repeatedly frames the next two quarters as a period of ‘ambiguity’ where the company is operationally busy but may not be able to revenue‑recognize until partner regulatory approvals materialize, shifting accountability externally.
• Capacity Build‑out Arms Race: OneSource positions its accelerated Phase 2 DDC expansion (200M+ units by end‑CY26, a year ahead) as both a competitive moat and a prerequisite to capture surging global GLP‑1 generic demand, with customer co‑investment validating the bet.
• Geographic & Customer De‑risking Beyond Canada: DRL’s likely Canada delay is framed as inconsequential because OneSource has relationships with other first‑wave filers and a broad base of 20+ customers across India, Brazil, Saudi Arabia, and MENA, all launching from March/April 2026.
• Biologics Resurgence as Second Engine: The biologics funnel has grown 4x year‑on‑year, powered by the Biosecure Act pushing innovators to seek new CDMOs and simplified biosimilar pathways in the US/EU; management signals the 4kL mammalian capacity will be fully absorbed and need rapid expansion.
• Inorganic Integration & Scale: The Poland and Brookes acquisitions are positioned as strategically and financially accretive, with pro‑forma H1 combined revenue of ~US$110M at 30% EBITDA, and will begin consolidating from FY27, underpinning the $500M FY28 target.
• CDMO Moat: End‑to‑End & Multi‑Modality: OneSource claims a unique competitive position as the only CDMO offering end‑to‑end drug‑device combination assembly across 10+ platforms, which creates stickiness and pricing power — this is ‘not a price game, an access game’.
• Semaglutide Global TAM Inflection: Management believes the addressable patient population for GLP‑1s is 1.5–2 billion and that no amount of capacity addition can outstrip demand in the near term; market formation across 70+ countries from March 2026 will be transformative.
• Working Capital & Debt Transience: Elevated working capital and net debt are framed as temporary — deliberately built to pre‑position inventory for DDC launches and fund capacity acceleration — with normalization expected over the medium term.

Operational commentary

• Stopped onboarding new DDC customers because current capacity is fully committed; expansion underway in phases
• 10 successful customer/regulatory inspections in Q2; 37 inspections completed in H1FY26
• 26 new RFPs added during the quarter across all modalities; 50‑plus RFPs currently active
• 12 customers are now common across multiple modalities, validating the cross‑selling thesis
• Biologics funnel has grown 4x versus FY25, driven by the US Biosecure Act and simplified biosimilar approval pathways in the US and Europe
• Soft‑gelatin business entering seasonally strong quarters, with robust interest in recently commissioned soft‑gel CDMO capacity
• Injectables scaling via organic capability additions plus the proposed Polish acquisition, which will position the company among leading sterile fill‑finish CDMOs
• Steriscience plant (FDA‑approved, ~20 years old) undergoing major capacity expansion and retrofit, expected online next year
• 8–10 customers expected to launch commercially in FY27 across multiple global markets
• Credit rating upgraded multiple times since January 2025 listing, now in the ‘A’ family; effective interest rate down 140 bps YoY to single digits
• DRL’s Canada launch may face a slight delay, but OneSource has relationships with other first‑wave filers to ensure participation at market formation
• India semaglutide approval already received by some partners; expect day‑one market presence

Analyst Q&A

• Q. How is OneSource de‑risking semaglutide exposure across geographies, and what is the customer concentration in Canada, Brazil, India, and MENA?

  Management stated that multiple customers — typically the #1 or top‑5 players — are present in each key market (Canada, Brazil, Saudi Arabia, India), but declined to name specific customers.

• Q. What is the realistic capacity utilization that can be achieved on the 220M‑unit headline DDC capacity?

  Explained that headline capacity never translates 1:1 to output due to changeovers and product mix; the adjusted deliverable capacity is lower, and CDMOs build ahead of demand. Advised focusing on the FY28 revenue guidance rather than unit math.

• Q. Do take‑or‑pay arrangements have conditionalities tied to customer regulatory approvals, and how much revenue can be recognized from them?

  Confirmed take‑or‑pay is take‑or‑pay, but noted revenue recognition depends on contract structure (capacity fees, capex contributions, shipment) and accounting standards; some portions may be recognized, others only on commercial shipment.

• Q. What is the likely share dilution from the two proposed mergers?

  Initially estimated approximately 2.5 Cr additional shares; committed to providing a precise number post‑call.

• Q. What is the revenue recognition policy for commercial supply agreements, and why might revenue not be recognized despite full capacity utilization in H2?

  Acknowledged revenue recognition follows accounting standards and varies by contract (take‑or‑pay, capex participation, shipment‑based). Emphasized that capacity is fully sold but commercial shipment — and hence recognition — depends on partner approvals.

Research and educational content only. Not investment advice.